Functional antibody delivery: Advances in cellular manipulation

Adv Drug Deliv Rev. 2023 Jan:192:114586. doi: 10.1016/j.addr.2022.114586. Epub 2022 Oct 22.

Abstract

The current therapeutic antibody market in the U.S. consists of 100 antibody-based products and their market value is expected to explode beyond $300 billion by 2025. These therapies are presently limited to extracellular targets due to the innate inability of antibodies to transverse membranes. To expand the number of accessible therapeutic targets, intracellular antibody delivery is necessary. Many delivery vehicles for antibodies have been used with some promising results, such as nanoparticles and cell penetrating polymers. Despite the success of these delivery platforms using model antibody cargo, there is a surprisingly small number of studies that focus on functional antibody delivery into the cytosol that also measures a cellular response. Antibodies can be designed for essentially unlimited targets, including proteins and DNA, that will ultimately control cell function once delivered inside cells. Advancement in cellular manipulation depends on the application of intracellularly delivering functional antibodies to achieve a desired result. This review focuses on the emerging field of functional antibody delivery which enables various cellular responses and cell manipulation.

Keywords: Apoptosis; Cell differentiation; Cell growth; Cell motility; Cell signaling; Membrane transduction; Protein expression.

Publication types

  • Review
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Antibodies
  • Cytosol / metabolism
  • DNA / metabolism
  • Drug Delivery Systems*
  • Humans
  • Nanoparticles*

Substances

  • Antibodies
  • DNA